31 January, 2022
aptaTargets will attend the International Stroke Conference 2022, the world’s premier meeting dedicated to the science and treatment of cerebrovascular disease and brain health, which takes place from 9-11 February in New Orleans (USA) and online.
Dr Marc Ribó, Chief Medical Officer of aptaTargets and Assistant Professor in the Stroke Unit at the Vall d’Hebron Hospital in Barcelona, and Dr Macarena Hernández, Chief Scientific Officer of aptaTargets, will present an eposter entitled APRIL trial: safety results of ApTOLL in stroke patients on 10 February, with the aim of showing the latest results from an ongoing Phase Ib/IIa clinical trial to assess the safety and biological effect of ApTOLL plus endovascular therapy in a population of acute ischemic stroke patients. For more information, please visit the ISC’s program.
ApTOLL is a novel single-stranded DNA molecule (aptamer) with immunomodulator and anti-inflammatory effect. Its activity focuses on blocking the activation of TLR4, a receptor located on the surface of immune cells responsible for initiating the inflammatory cascade that leads to the death of neurons and the consequent worsening of brain injuries. ApTOLL is the only drug in development for the treatment of acute ischemic stroke that blocks the activation of TLR4.